LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce that its clinical research operations in Belfast, Northern Ireland UK, have received authorization from their competent authority, the Medicines and Healthcare product Regulatory Agency (MHRA) to have importation of IMPs added to their manufacturing (MIA(IMP)) license. The addition to the license enables the elimination of a third party vendor to import IMPs on behalf of Celerion thereby saving time, cost and initiating direct communication with clients to expedite early stage clinical studies.
